TLRY

Tilray Brands, Inc.

Nasdaq· Medicinal Chemicals & Botanical Products· CIK 0001731348 Cannabis

$2.72 −0.09 (−3.20%)

Oct 26 4:00 PM ET · prev $2.81

Market cap

$433.0M

Small cap

Consensus

Buy

47% Buy or better · 17 analysts

Median target

$4.00

+47% · range $4.00–12.00

1 year

−81.5%

from $14.70 · Oct 27

30 days

−32.3%

from $4.02

52-week range

$2.72–14.70

at the low

Avg volume 20D

4.51M

shares / day

Short interest

18.79M

≈12.7% of shares · −3.2%

Days to cover

5.2

at average volume

Insider net

+$69.2K

3 buyers · 0 sellers · since Jul 29

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 3 reports · 90 days

Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 3/3

Strongest BEARISH Tilray Brands reported Q1 FY2027 revenue of $257.1M, up 23% YoY and a record. GAAP net loss was $40.0M…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 2 Tilray Brands completed the acquisition of key BrewDog assets, inclu…
R Apr 1 Tilray Brands reported Q3 fiscal 2026 results with net revenue of $2…
R Apr 15 Tilray Brands is conducting an at-the-market offering of up to $180…
R Apr 15 Tilray Brands announced the acquisition of UK-based medical cannabis…
X Jul 31 Short interest jumps 28.5% to 20.85M
B Aug 3 to Aug 6 3 days of insider buys: $69.2K by 3 insiders, avg $4.62
E Oct 8 Earnings: TLRY Q3 2026 Earnings: EPS $-0.32 (-55.8% vs est)
R Oct 8 Tilray Brands reported Q1 FY2027 revenue of $257.1M, up 23% YoY and…

Signal stack

Where each data set points today.

InsidersBULLISH

3 insiders bought $69.2K at an average $4.62. No open-market sales. Price is 41% below their cost.
InstitutionsBULLISH

Q2 2026: 15 added (0 new), 9 trimmed or exited.
AnalystsBULLISH

8 of 17 rate it Buy or better. Every target is above the price.
Short sellersSTEADY

Short interest −3.2% to 18.79M shares. 5.2 days to cover, ≈12.7% of shares.
TrendDOWNTREND

31% below its 50-day average. New closing low $2.72 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
SUSQUEHANNA INTERNATIONAL GROUP, LLP	ADD	1,021,777	$4.6M
MORGAN STANLEY	ADD	995,145	$4.5M
CITADEL ADVISORS LLC	DOUBLED	868,147	$3.9M
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	ADD	646,762	$2.9M
UBS Group AG	TRIM	454,184	$2.0M
STATE STREET CORP	ADD	384,123	$1.7M
GOLDMAN SACHS GROUP INC	ADD	208,274	$935.1K
D. E. Shaw & Co., Inc.	TRIM	148,383	$666.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts

Buy 47% rate it Buy or better

Strong Buy3Buy5Hold9Sell0Strong Sell0

12-month targets · 9 analysts

$2.72 $4.00 $4.00 $12.00

Price is below the lowest target. Median implies +47%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 9, 2026	Canaccord Genuity MAINTAIN	MAINTAIN	Hold
Jul 14, 2026	TD Cowen MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

$69.2K

bought · 3 insiders

sold · 0 insiders

−41.1%

vs their $4.62 cost

Date	Insider	Type	Value
Aug 26, 2026	FALTISCHEK DENISE M Chief Strategy Officer	TAX W/H	$310.4K
Aug 26, 2026	Gendel Mitchell Global General Counsel	TAX W/H	$283.9K
Aug 26, 2026	Gendel Mitchell Global General Counsel	EXERCISE	109,748 sh
Aug 26, 2026	FALTISCHEK DENISE M Chief Strategy Officer	TAX W/H	$150.5K
Aug 26, 2026	FALTISCHEK DENISE M Chief Strategy Officer	EXERCISE	58,204 sh
Aug 26, 2026	FALTISCHEK DENISE M Chief Strategy Officer	EXERCISE	120,017 sh
Aug 26, 2026	Gendel Mitchell Global General Counsel	TAX W/H	$130.8K
Aug 26, 2026	Gendel Mitchell Global General Counsel	EXERCISE	50,556 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	$0.00	$0.00–$0.00	-100.0%	$265.6M
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only